Obstetric cholestasis with elevated gamma glutamyl transpeptidase: Incidence, presentation and treatment

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 11, 2003, Pages 1283-1286

  Milkiewicz, Piotr ^a,d   Gallagher, Ruth ^b   Chambers, Jenny ^c   Eggington, Enid ^a   Weaver, Judith ^c   Elias, Elwyn ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b SELLY OAK HOSPITAL   (United Kingdom)

^c Maternity Hospital   (United Kingdom)

^d POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Gamma glutamyl transpeptidase (GGT); Obstetric cholestasis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DELIVERY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENERAL CONDITION IMPROVEMENT; GESTATIONAL AGE; HISTORY; HUMAN; INCIDENCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; OBSTETRIC CHOLESTASIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PRURITUS; UNITED KINGDOM;

EID: 0345304390     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03171.x     Document Type: Article

References (12)

1. Milkiewicz P, Williamson C, Weaver J, Elias E. Obstetric cholestasis. BMJ 2002; 324: 123-4.
2. Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J. Hepatol. 2000; 33: 1012-21.
3. Jacquemin E, Cresteil D, Manouvrier S et al. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353: 210-1.
4. Elias E. URSO in obstetric cholestasis: not a bear market. Gut 1999; 45: 331-2.
5. Jansen PLM, Muller M. The molecular genetics of familial intrahepatic cholestasis. Gut 2000; 47: 1-5.
6. Dixon PH, Weerasekera N, Linton KJ et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Mol. Genet. 2000; 9: 1209-17.
7. Davies MH, da Silva RC, Jones SR, Weaver JB, Elias E. Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Gut 1995; 37: 580-4.
8. Palma J, Reyes H, Ribalta J et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with palcebo. J. Hepatol. 1997; 27: 1022-8.
9. Meng LJ, Reyes H, Palma J et al. Effects of ursodeoxycholec acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy. J. Hepatol. 1997; 27: 1029-40.
10. Brites D, Rodrigues CM. Elevated levels of bile acids in colostrum of patients with cholestasis of pregnancy are decreased following ursodeoxycholic acid therapy. J. Hepatol. 1998; 29: 743-51.
11. Milkiewicz P, Roma MG, Mills CO et al. Tauroursodeoxycholate (TUDCA) protects against redistribution of multidrug resistant protein 2 (Mrp2) and disruption of F-actin caused by taurolithocholate (TLC): A study in isolated rat hepatocyte couplets. Hepatology 1999; 30: 461A.
12. Beuers U, Bilzer M, Chittuattu A et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001; 33: 1206-16.